Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.33 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2723184 | 1.00 | STK17B (0.41) | STK17BSTK17AP2RX7NPFFR1NPFFR2 | |
| SCHEMBL2724824 | 0.99 | STK17B (0.41) | STK17BSTK17AP2RX7NPFFR1NPFFR2 | |
| SCHEMBL29437376 | 0.99 | STK17B (0.41) | STK17BSTK17AP2RX7NPFFR1NPFFR2 | |
| SCHEMBL20926951 | 0.92 | STK17B (0.40) | STK17BSTK17ANPFFR1NPFFR2SYK | |
| SCHEMBL21014235 | 0.90 | P2RX7 (0.33) | STK17BSTK17AP2RX7NPFFR1NPFFR2 | |
| SCHEMBL20980340 | 0.90 | STK17B (0.38) | STK17BSTK17ANPFFR1NPFFR2 | |
| SCHEMBL20980348 | 0.90 | STK17B (0.38) | STK17BSTK17ANPFFR1NPFFR2 | |
| SCHEMBL20913363 | 0.89 | — | — | |
| SCHEMBL20696694 | 0.88 | — | — | |
| SCHEMBL20835356 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11717523-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | STK17B 1245/4885STK17A 1696/4885P2RX7 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.